NCT01194050已完成不适用
Erlotinib (Tarceva) in Routine Clinical Practice for First Line Maintenance Therapy (1LM) in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 289
- 主要终点
- Overall survival at 1 year
研究概览
简要总结
This observational study will investigate the tolerability and efficacy of Tarceva (erlotinib) in daily clinical practice under routine conditions in patients with locally advanced or metastatic non small cell lung cancer. Data will be collected for approximately 12 months.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients with locally advanced or metastatic non-small cell lung cancer (stage IIIb or IV) with stable disease after 4 cycles of standard platinum-based first-line chemotherapy
排除标准
- •Not willing or not able to sign written informed consent form
结局指标
主要结局
Overall survival at 1 year
时间窗: 12 months
次要结局
- Reproducibility of the results of the controlled SATURN study(12 months)
- Tolerability of Tarceva in daily clinical practice under routine conditions(12 months)
- Efficacy of Tarceva in daily clinical practice under routine conditions(12 months)
研究者
相似试验
已完成
不适用
An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerNCT01535729Hoffmann-La Roche465
已完成
不适用
An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)Non-Squamous Non-Small Cell Lung CancerNCT01836133Hoffmann-La Roche70
已完成
不适用
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung CancerNonsquamous Nonsmall Cell Neoplasm of LungNCT01161173Hoffmann-La Roche347
进行中（未招募）
不适用
A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptorocally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor.MedDRA version: 14.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023869-21-FIRoche Oy
已完成
2 期
BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Lung CancerNCT00411632M.D. Anderson Cancer Center37